Uveal disorder

This early-phase trial is testing whether the immunotherapy drug nivolumab can help people with melanoma or lung cancer that has spread to the leptomeninges (the lining of the brain and spinal cord). The drug is given both through a vein and directly into the spinal fluid via a l…

This phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…

This study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could better slow cancer growth. Participants were randomly assigned to receive either tram…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This phase 2 trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink tumors in people with metastatic uveal melanoma, a rare and aggressive eye cancer. Participants receive chemotherapy to prepare their immune system, then an infu…

This phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…

This study tests whether baricitinib, an oral drug, is safe and effective for children aged 2 to 18 with active uveitis (eye inflammation) linked to juvenile arthritis or a related condition. Participants had not responded well to standard treatments. The main goal is to reduce e…

This study tests a small implant placed inside the eye to help drain fluid and lower pressure in people with open-angle or narrow-angle glaucoma. It is for adults whose eye pressure is not well controlled with eye drops. The main goal is to see if the implant safely reduces press…

This study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is …

This study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and help control the disease.

This study tests whether combining two drugs, binimetinib and belinostat, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 7 adults with this condition are taking part. The main goal is to see how many patients respond to the tr…

This early-phase trial tests a radioactive drug called 225Ac-MTI-201 in 16 people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The main goal is to find the highest safe dose and understand side effects. Participants receive a singl…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study tests a treatment that uses a patient's own immune cells (T-cells) to fight advanced melanoma. Some participants also receive a dendritic cell vaccine to boost the immune response. The goal is to see if the T-cells last longer and work better against the cancer. The tr…

This phase 2 trial tests whether sunitinib or valproic acid can prevent uveal melanoma, a rare eye cancer, from spreading to other parts of the body in high-risk patients. 210 participants who have already had their primary tumor treated are randomly assigned to receive one of th…

This phase 2 trial tests darovasertib, a daily pill, in 160 people with uveal melanoma (a rare eye cancer). The drug is given before and after standard treatments like surgery or radiation. The main goals are to see if the pill can shrink tumors enough to avoid eye removal, reduc…

This early-phase trial tests a single injection of a gene therapy called RTx-015 in 10 adults with retinitis pigmentosa or choroideremia, two inherited conditions that cause vision loss. The therapy delivers a gene that makes retinal cells produce a light-sensitive protein, poten…

This study tests a combination of two oral drugs, darovasertib and crizotinib, against standard treatments (immunotherapy or chemotherapy) in 420 people with a specific type of advanced eye melanoma that has spread. Participants must have a certain genetic marker (HLA-A2 negative…

This phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to…

This study tests an oral medication called brepocitinib in adults with active uveitis, a condition causing inflammation inside the eye. The goal is to see if the drug can prevent the disease from worsening and help maintain vision. About 371 participants will receive either the d…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This phase II trial tests whether combining pembrolizumab (an immunotherapy) with lenvatinib (a targeted therapy) can control metastatic uveal melanoma, a rare eye cancer that has spread. About 51 adults are enrolled in two groups: those who have never taken Tebentafusp and those…

This early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tum…

This study tests a new device called the VividWhite Glaucoma Implant, which is surgically placed in the eye to help lower pressure in people with glaucoma. Sixty-five participants will be followed for 12 months to see if the implant safely reduces eye pressure and lessens the nee…

This study tests whether taking nicotinamide and pyruvate supplements can help protect the eyes of people with open-angle glaucoma. About 250 adults aged 35 to 85 will take either the supplements or a placebo for 20 months, while continuing their standard glaucoma medications. Th…

This study compares different ways of performing a laser treatment called selective laser trabeculoplasty (SLT) for people with open-angle glaucoma or high eye pressure. 400 participants will receive SLT using one of several protocols, and researchers will track how much their ey…

This study aimed to test a special vaccine made from modified melanoma cells to help the immune system fight remaining cancer in people with high-risk or low-burden melanoma. It was designed for patients with certain genetic markers and stages of melanoma. However, the study was …

This study looks at the best way to repeat a laser treatment called SLT for people with open-angle glaucoma or high eye pressure. Researchers will compare different treatment methods in 400 participants who were already in an earlier SLT trial. The goal is to see how well repeat …

This early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injectio…

This study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus a chemotherapy drug (melphalan) given directly to the liver through a special procedure. It includes 83 adults with advanced uveal melanoma that has spread mainly to the liver. The goal is t…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving ne…

This study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatme…

This pilot study examines proteins in the vitreous (the gel-like fluid inside the eye) of patients with pseudoexfoliation syndrome (PEX), a condition that can lead to glaucoma. Researchers will compare protein levels between eyes with and without PEX in 24 adults undergoing eye s…

This study tests whether a video-based educational program can help people who have had uveal melanoma (a rare eye cancer) better understand their disease and feel more in control. About 108 adults who completed treatment are randomly assigned to watch the video or receive usual …

This study is testing a new software that measures eye inflammation from standard images taken during routine care. Researchers will enroll 50 people with uveitis, an inflammatory eye disease, to see if the software can detect meaningful changes in inflammation. The goal is to he…

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This study follows 46 people with gyrate atrophy, a rare genetic condition that causes vision loss, over 4 years. Researchers measure ornithine levels in the blood and track changes in the retina using eye scans and photos. The goal is to learn how the disease progresses under st…

This study tests whether analyzing fluid from the eye can predict which immunosuppressive drug will work best for people with non-infectious uveitis, an eye inflammation condition. About 220 participants who haven't responded well to steroids will provide eye fluid and blood samp…

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…

This study offers free vision screenings to underserved adults over 40 living in affordable housing in Harlem and Washington Heights. The goal is to find eye problems like glaucoma, cataracts, and diabetic retinopathy early and connect people with follow-up care. About 749 partic…

This study reviews medical records of 200 people in Singapore with inflammatory eye diseases like uveitis and scleritis. Researchers want to understand who gets these conditions, what treatments they receive, and how they do over time. No new treatments are being tested—this is p…